Dystrophic Epidermolysis Bullosa Management Market Snapshot (2023 to 2033)
The global dystrophic epidermolysis bullosa management market is expected to reach US$ 452.37 Million in 2023 and is projected to exhibit a CAGR of 5.7% from 2023 to 2033. The high prevalence of skin diseases and the high incidence of dystrophic epidermolysis bullosa management are the major factors driving the global market for dystrophic epidermolysis bullosa management.
Children with RDEB may develop malignant melanoma and adults with EB simplex are at a very high risk of basal cell carcinoma. Patient-centered approach to treating EB is expected to further grow in the market. In order for a plan to be tailored to each individual patient, healthcare professionals use preventative measures, nutritional support, and wound care treatments. In addition to monitoring and updating the patient's treatment plan, assessment of skin lesions and general health tools are expected to grow.
The outcome of antibiotic treatment depends on the infectious status of the wound and the result of an antibiogram. As a result of the recommended strategies, dermatologists will be able to develop individualized care plans for patients with EB. The proposed monitoring instruments can be used to continuously update the treatment plan for the patient, as well as the national recommendations for the management of EB, based on the data provided by the proposed monitoring tools. Further, it may be possible to offer whole exome sequences or targeted panels as part of the next-generation sequencing process. Low cost and rapid turnaround time will be provided by targeted panels that include the testing of commonly found genes with 94.3% efficiency and 75-98 sensitivity.
Data Points
Key Statistics
Estimated Base Year Value (2022)
US$ 430 million
Expected Market Value (2023)
US$ 452.37 million
Anticipated Forecast Value (2033)
US$ 787.8 million
Projected Growth Rate (2023 to 2033)
5.7% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Dystrophic Epidermolysis Bullosa Management Market Demand Analysis vs. Forecast 2023 to 2033
The global demand for dystrophic epidermolysis bullosa management is projected to increase at a CAGR of 5.7% during the forecast period between 2023 and 2033, reaching a total of US$ 787.8 Million in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 5.2%.
On the basis of incidence, data show that 50 new cases of epidermolysis bullosa occur every million live births. In 92% of these cases, the epidermolysis bullosa is simplex. In 5% of these cases, the epidermolysis bullosa is dystrophic. In 1% of these cases, it is junctional. Depending on the country and ethnicity, these data may differ significantly. Romanian researchers have identified 72 families with an epidermolysis bullosa variant.
As part of the treatment for the wound, bandages, and dressings that do not adhere to the wound are used to protect it, moisturizers are applied to reduce friction and itching, and pain relievers are prescribed to relieve symptoms. There is a lot of complexity and evolution in the management of dystrophic epidermolysis bullosa. Understanding the underlying cause and mechanisms of the disease is being improved through research into genetics and biology.
The research has opened up new opportunities for developing treatments, including gene therapies and stem cell therapies. Moreover, advances in therapies, nutrition, and pain management will help individuals with dystrophic epidermolysis bullosa to lead a better quality of life. In order to continue improving the lives of those affected, further research into the disease will be explored.
What are the Major Drivers Behind the Dystrophic Epidermolysis Bullosa Market?
Increased Adoption of Genetic Therapies to Boost Treatment and Care
Growing consumer awareness of DEB and advanced treatments for this disease is expected to boost the market over the next few years. It is anticipated that the number of people suffering from dystrophic epidermolysis bullosa will continue to rise and that innovative treatments will soon be launched to address this disease.
Research and development advances will lead to a global market expansion for dystrophic epidermolysis bullosa treatment over the forecast period. As a result of advancements in gene panels across epidermolysis bullosa centers for treatment, whole-exome sequencing has revolutionized dystrophic epidermolysis bullosa treatment and diagnostics. It is expected that the market is further anticipated to grow due to increasing consumer spending power and economic growth.
As biologics and biosimilars are more effective at treating diseases, the demand for newer, technologically enhanced products is growing in the market. Due to this fact, major players that operate in the field of pharmaceuticals invest in research to come up with new drugs to treat DEB in the market. In the forecast period, key players are expected to invest more in research and development activities.
Scientific Development to Expand the Market for Dystrophic Epidermolysis Bullosa Management
New drugs and technological advances have positively impacted the market for dystrophic epidermolysis bullosa management. In recent years, new drugs and improved diagnosis and treatment protocols have improved treatment efficiency for dystrophic epidermolysis bullosa management infection.
As science has advanced rapidly in recent years, a variety of therapeutic strategies for treating EB now appear to be promising and grow the market. In order to determine priority research areas for the EB community, the scientific and clinical communities are working in close collaboration. In addition to being active and successful in fundraising, many patient advocacy organizations provide funds for the clinical research project as well. Numerous therapies are currently in preclinical development, with the first ones having already advanced to phase 1/2 or 3 clinical trials. In addition to these factors, the market for DEB management is expected to experience strong growth in the coming years.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Associated with Dystrophic Epidermolysis Bullosa Management?
Low Awareness about Diseases and the High Cost of Drugs will Hamper the Market
The limited cure for these diseases is likely to further hamper the market growth in the future. As a result of the high cost of diseases and medications, the growth of the market is expected to be further constrained. A decrease in supportive care for these types of diseases is expected to negatively impact the market. Severe skin fragility can cause significant emotional and physical distress for patients with DEB. Quality of life can be greatly affected by this, which can have a major impact on the market.
As DEB is a rare disorder, there is still a lack of awareness about the condition in many parts of the world. As a result, patients may be unable to receive the appropriate support and care that they require. A survey has demonstrated that epidermolysis bullosa burdens patients, their loved ones, and healthcare professionals. Patients with epidermolysis bullosa and their caregivers must compromise their educational and career goals due to the limitations caused by the disease. Additionally, the financial burden is a significant impact on epidermolysis bullosa in patients.
For instance, the National Center for Biotechnology Information reported on September 8, 2020, that epidermolysis bullosa bandage costs ranged between US$ 262 and over US$ 2000 per month.
Region Wise Insights
What is the Projected Growth Rate of the North American Dystrophic Epidermolysis Bullosa Management Market?
Hospitals that Specialize in Treating Dystrophic Epidermolysis Bullosa to Grow the Market
Globally, North American markets are forecast to account for 23% of the overall market. According to projections, North America will dominate the global market for dystrophic epidermolysis bullosa management. Due to developing healthcare infrastructure, increased grants for rare diseases, and technological advancements.
A study conducted by the USA National Epidermolysis Bullosa Registry indicates that epidermolysis bullosa occurs in 19.6 out of 1 million live births and is prevalent in 11.07 out of 1 million live births. It was estimated that 7.87 cases and six cases were diagnosed per million live births, respectively, for epidermolysis bullosa simplex.
As a result of the presence of a large number of pharmaceutical and biotech companies, coupled with a well-developed healthcare infrastructure, North America is the largest market for the dystrophic epidermolysis bullosa management market. Additionally, there are several other factors that contribute to the growth of the EB market in North America, including the high prevalence of EB in the region, the growth of awareness about EB and its treatment, and the EB-related products and services are supporting the market's growth.
What are the Prospects for the Dystrophic Epidermolysis Bullosa Management Market in Europe?
Europe is projected to grow at a CAGR of 2.6% during the forecast period. Industry forecasts predict that the European market will grow at the fastest rate in the next few years. The large population of Europe and increasing awareness of dystrophic epidermolysis bullosa make it a desirable market for dystrophic epidermolysis bullosa management. Inflammatory new diseases such as dystrophic epidermolysis bullosa are becoming more prevalent as disposable income and treatment options increase in this region.
The region is also home to some of the world's most advanced healthcare systems, which allow clients to access treatments for rare diseases such as dystrophic epidermolysis bullosa. In addition, the European healthcare system is well-developed and highly funded, which makes it easier for patients suffering from rare diseases such as dystrophic epidermolysis bullosa to get the best available treatment. Moreover, the region is home to several elite companies that specialize in dystrophic epidermolysis bullosa management, and as a result, it is leading innovation and the development of new treatments in the field.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category Wise Insights
By Drug Class, Which Segment of the Market is Expected to Accelerate Sales?
Antibiotics to Boost Dystrophic Epidermolysis Bullosa Management Market Growth
Due to rising research and development and product launches, antibiotics are expected to account for the largest share of the market during the forecast period. Antibiotics are expected to hold a market share of 32% by 2023. Antibiotics are becoming a more common treatment option for DEB, and this will lead to a growing market for DEB management. DEB has become more prevalent as more people are able to access treatments that improve their quality of life.
A rare skin condition characterized by fragile, blistering skin, dystrophic epidermolysis bullosa (DEB), has been found to respond well to antibiotic treatment. In the case of DEB, antibiotics can be used as an effective treatment in order to reduce the risk of bacterial infections that might occur and to treat infections. Aside from this, they can also be used to alleviate inflammation from the condition, reduce the amount of pain associated with it, as well as stop blisters from forming, and reduce the formation of new ones.
By Distribution Channel, Which Channel is Expected to Gain Better Traction in the Market?
Hospital Pharmacies to be the Most Promising Segment for Dystrophic Epidermolysis Bullosa Management Market
Health consciousness and aging populations are projected to drive the hospital pharmacy business. The hospital pharmacy sector is expected to grow at a compound annual growth rate of 3.4% during the forecast period. Pharmacy services, therapies, and medications offered through hospital pharmacies help treat dystrophic epidermolysis bullosa.
Using the latest advances in technological advances, pharmacies are developing and delivering tailored treatment plans based on individual patient needs, tailoring the treatment plan appropriate to the patient's needs. A few of these measures involve giving pharmacists access to debilitating medications specifically formulated to treat DEB, providing information on the best options for treatment, and giving access to pharmacists that are familiar and experienced with treating DEB.
Also, hospitals are working closely with their own development teams to come up with new treatments and therapies to be used for DEB patients that can be adapted to their specific needs through their own research and development. Hospital pharmacies help grow the DEB management market by providing patients with the latest medications and therapies.
The Start-up Ecosystem: How will Startups Fare in the Future?
Startups in the field of dystrophic epidermolysis bullosa management include the following:
Krystal Biotech is a US-based gene therapy company developing treatments for dystrophic epidermolysis bullosa. An HSV-1-based vector is being used to fix defects in the COL7A1 gene in the company's lead candidate KB103, to treat dystrophic epidermolysis bullosa. A topical formulation and an intradermal formulation of KB103 have been tested in preclinical studies. Founders own 2/3rds of the company via a family trust as of Aug.2017, and Sun Pharma invested USD 7M for 16.5%. A second gene therapy candidate, KB104, is being developed by the company as well.
FIBRX is developing a product to treat skin diseases by preventing scarring through the application of a therapeutic agent. For treating dystrophic epidermolysis bullosa, a disease that causes blisters on the skin, the company is developing recombinant human decorin gel formulations. Extracellular matrix structural components are developed and repaired with the help of the protein binding to collagen.
Competitive Landscape
Researchers and developers are developing new products and devices for diagnosis and treatment in the global dystrophic epidermolysis bullosa management market. These new developments are expected to lead to a number of new treatments being launched within the next few years. Companies have a competitive advantage over their competitors when they obtain approval for new products in a timely manner.
In January 2023, Krystal Biotech, Inc. announced that it had received approval from the USA Food and Drug Administration (FDA) informed the Company that the PDUFA date has been revised to May 19, 2023, as a result of manufacturing information the Agency received from the Company on December 20, 2022, in response to a regulatory update for B-VEC to treat patients with Dystrophic epidermolysis bullosa. Labeling discussions have also been pushed back until April 20, 2023. A replacement hardware unit was included in the manufacturing information submitted by the Company, as well as comparable data supporting its use.
Amryt, an international biopharmaceutical company dedicated to developing, commercializing, and acquiring proprietary treatments for rare diseases, has announced that Phase 3 of the APH-19 trial showed positive results with lomitapide in children with HoFH (homozygous familial hypercholesterolemia).
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 452.37 million
Market Value in 2033
US$ 787.8 million
Growth Rate
CAGR 5.7%
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Disease Type
Drug Class
Distribution Channel
Region
Regions Covered
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Key Countries Profiled
United States
Canada
Brazil
Mexico
Germany
United Kingdom
France
Spain
Italy
India
Malaysia
Singapore
Thailand
China
Japan
South Korea
Singapore
Australia
New Zealand
GCC Countries
South Africa
Israel
Key Companies Profiled
Castle Creek Biosciences
Amryth Pharma
Krystal Biotech
Abeona Therapeutics
BridgeBio
Phoenix Tissue Repair
Wings Therapeutics
InMed Pharmaceuticals, Inc.
Regenerx Biopharmaceuticals Inc.
Holostem Terapie Avanzate S.r.l.
Customization
Available Upon Request
Key Segments Profiled in the Dystrophic Epidermolysis Bullosa Management Industry Survey?
By Disease Type:
Dominant Dystrophic Epidermolysis Bullosa (DDEB)
Recessive Dystrophic Epidermolysis Bullosa (RDEB)
By Drug Class:
Antibiotics
Corticosteroids
Opioid Analgesics
Anticonvulsant
By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East & Africa
Frequently Asked Questions
How Big is the Dystrophic Epidermolysis Bullosa Management Market?
The market is estimated to reach US$ 452.37 million in 2023.
Who are the Key Players of the Dystrophic Epidermolysis Bullosa Management Market?
Amryth Pharma, Krystal Biotech, and BridgeBio are the key players in the market.
What is the Projected Market Valuation by 2033?
The market is estimated to secure a valuation of US$ 787.8 million by 2033.
What is the Growth Potential of the Market?
The growth potential of the market is 5.7% CAGR through 2033
What Drives Sales of the Market?
Increased adoption of genetic therapies boosts treatment and care.
Table of Content
1. Executive Summary | Dystrophic Epidermolysis Bullosa Management Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033
5.3.1. Dominant Dystrophic Epidermolysis Bullosa (DDEB)
5.3.2. Recessive Dystrophic Epidermolysis Bullosa (RDEB)
5.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
6.3.1. Antibiotics
6.3.2. Corticosteroids
6.3.3. Opioid Analgesics
6.3.4. Anticonvulsant
6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. Middle East and Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. United States of America
9.2.1.2. Canada
9.2.2. By Disease Type
9.2.3. By Drug Class
9.2.4. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Disease Type
9.3.3. By Drug Class
9.3.4. By Distribution Channel
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Disease Type
10.2.3. By Drug Class
10.2.4. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Disease Type
10.3.3. By Drug Class
10.3.4. By Distribution Channel
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Disease Type
11.2.3. By Drug Class
11.2.4. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Disease Type
11.3.3. By Drug Class
11.3.4. By Distribution Channel
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Singapore
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Disease Type
12.2.3. By Drug Class
12.2.4. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Disease Type
12.3.3. By Drug Class
12.3.4. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Disease Type
13.2.3. By Drug Class
13.2.4. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Disease Type
13.3.3. By Drug Class
13.3.4. By Distribution Channel
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Disease Type
14.2.3. By Drug Class
14.2.4. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Disease Type
14.3.3. By Drug Class
14.3.4. By Distribution Channel
14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. GCC Countries
15.2.1.2. South Africa
15.2.1.3. Israel
15.2.1.4. Rest of MEA
15.2.2. By Disease Type
15.2.3. By Drug Class
15.2.4. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Disease Type
15.3.3. By Drug Class
15.3.4. By Distribution Channel
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. United States of America
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Disease Type
16.1.2.2. By Drug Class
16.1.2.3. By Distribution Channel
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Disease Type
16.2.2.2. By Drug Class
16.2.2.3. By Distribution Channel
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Disease Type
16.3.2.2. By Drug Class
16.3.2.3. By Distribution Channel
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Disease Type
16.4.2.2. By Drug Class
16.4.2.3. By Distribution Channel
16.5. Germany
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Disease Type
16.5.2.2. By Drug Class
16.5.2.3. By Distribution Channel
16.6. United Kingdom
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Disease Type
16.6.2.2. By Drug Class
16.6.2.3. By Distribution Channel
16.7. France
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Disease Type
16.7.2.2. By Drug Class
16.7.2.3. By Distribution Channel
16.8. Spain
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Disease Type
16.8.2.2. By Drug Class
16.8.2.3. By Distribution Channel
16.9. Italy
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Disease Type
16.9.2.2. By Drug Class
16.9.2.3. By Distribution Channel
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Disease Type
16.10.2.2. By Drug Class
16.10.2.3. By Distribution Channel
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Disease Type
16.11.2.2. By Drug Class
16.11.2.3. By Distribution Channel
16.12. Singapore
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Disease Type
16.12.2.2. By Drug Class
16.12.2.3. By Distribution Channel
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Disease Type
16.13.2.2. By Drug Class
16.13.2.3. By Distribution Channel
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Disease Type
16.14.2.2. By Drug Class
16.14.2.3. By Distribution Channel
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Disease Type
16.15.2.2. By Drug Class
16.15.2.3. By Distribution Channel
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Disease Type
16.16.2.2. By Drug Class
16.16.2.3. By Distribution Channel
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Disease Type
16.17.2.2. By Drug Class
16.17.2.3. By Distribution Channel
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Disease Type
16.18.2.2. By Drug Class
16.18.2.3. By Distribution Channel
16.19. GCC Countries
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Disease Type
16.19.2.2. By Drug Class
16.19.2.3. By Distribution Channel
16.20. South Africa
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Disease Type
16.20.2.2. By Drug Class
16.20.2.3. By Distribution Channel
16.21. Israel
16.21.1. Pricing Analysis
16.21.2. Market Share Analysis, 2022
16.21.2.1. By Disease Type
16.21.2.2. By Drug Class
16.21.2.3. By Distribution Channel
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Disease Type
17.3.3. By Drug Class
17.3.4. By Distribution Channel
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. Castle Creek Biosciences
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Amryth Pharma
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Krystal Biotech
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. Abeona Therapeutics
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. BridgeBio
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Phoenix Tissue Repair
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Wings Therapeutics
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. InMed Pharmaceuticals, Inc.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Regenerx Biopharmaceuticals Inc
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. Holostem Terapie Avanzate S.r.l.
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 7: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 11: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 15: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: South Asia Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 19: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 20: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: East Asia Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 23: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 24: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 26: Oceania Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 27: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 28: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 30: MEA Market Value (US$ Million) Forecast by Disease Type, 2018 to 2033
Table 31: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 32: MEA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 9: Global Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 10: Global Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 11: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 12: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 13: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 17: Global Market Attractiveness by Disease Type, 2023 to 2033
Figure 18: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 19: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 20: Global Market Attractiveness by Region, 2023 to 2033
Figure 21: North America Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 22: North America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 23: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 29: North America Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 30: North America Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 31: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 32: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 33: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 37: North America Market Attractiveness by Disease Type, 2023 to 2033
Figure 38: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 39: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 40: North America Market Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 42: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 43: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 49: Latin America Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 51: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 52: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 57: Latin America Market Attractiveness by Disease Type, 2023 to 2033
Figure 58: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 59: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 61: Europe Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 62: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 63: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 69: Europe Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 70: Europe Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 71: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 72: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 73: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 77: Europe Market Attractiveness by Disease Type, 2023 to 2033
Figure 78: Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 79: Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 80: Europe Market Attractiveness by Country, 2023 to 2033
Figure 81: South Asia Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 82: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 83: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: South Asia Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 89: South Asia Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 91: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 92: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 94: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 95: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 97: South Asia Market Attractiveness by Disease Type, 2023 to 2033
Figure 98: South Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 99: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033
Figure 101: East Asia Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 102: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 103: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: East Asia Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 109: East Asia Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 111: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 112: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 114: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 115: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 117: East Asia Market Attractiveness by Disease Type, 2023 to 2033
Figure 118: East Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 119: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 121: Oceania Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 122: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 123: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033
Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 128: Oceania Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 129: Oceania Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 131: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 132: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 134: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 137: Oceania Market Attractiveness by Disease Type, 2023 to 2033
Figure 138: Oceania Market Attractiveness by Drug Class, 2023 to 2033
Figure 139: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033
Figure 141: MEA Market Value (US$ Million) by Disease Type, 2023 to 2033
Figure 142: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 143: MEA Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033
Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 148: MEA Market Value (US$ Million) Analysis by Disease Type, 2018 to 2033
Figure 149: MEA Market Value Share (%) and BPS Analysis by Disease Type, 2023 to 2033
Figure 150: MEA Market Y-o-Y Growth (%) Projections by Disease Type, 2023 to 2033
Figure 151: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 152: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 153: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 154: MEA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 157: MEA Market Attractiveness by Disease Type, 2023 to 2033
Figure 158: MEA Market Attractiveness by Drug Class, 2023 to 2033
Figure 159: MEA Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
